Search Results

You are looking at 211 - 220 of 578 items for :

  • Refine by Access: All x
Clear All
Full access

Stabilization of Metastatic Uterine Leiomyosarcoma Using Pembrolizumab

Katherine Cotangco, Mary Meram, and M. Patrick Lowe

a 90% PD-L1 expression. The assay also confirmed estrogen and progesterone receptor negativity, pTEN positivity, and mismatch repair status stability ( Table 1 ). After cycle 8, the patient began experiencing dyspnea and fatigue. Her CT scans showed

Full access

Novel Agents for Metastatic Triple-Negative Breast Cancer: Finding the Positive in the Negative

Neelima Vidula, Leif W. Ellisen, and Aditya Bardia

). Talazoparib is FDA approved for HER2-negative advanced breast cancer with germline BRCA1/2 mutations. 17 Both olaparib and talazoparib are well tolerated, but toxicity includes myelosuppression, fatigue, and gastrointestinal problems. The BROCADE 3 phase

Full access

Introduction: Addressing Challenges in Multiple Myeloma Management in an Era of New Therapeutics

Sundar Jagannath

managed with dose reduction, schedule modification, optimized agent sequencing, or a combination of nonpharmacologic and pharmacologic therapy for symptom relief. They also discuss asthenia (fatigue), an important topic that is too infrequently addressed

Full access

Advances in Personalized Therapeutic Approaches in Myelodysplastic Syndromes

Rafael Bejar

65-year-old healthy man who presented with fatigue and shortness of breath, Dr. Bejar illustrated how genetic testing is used to generate a personalized risk assessment that will inform treatment. After a bone marrow biopsy revealed a hypercellular

Full access

The Changing Treatment Landscape for Metastatic Urothelial Carcinoma

Thomas W. Flaig

with chemotherapy (21% vs 11%). Most of the responses were in the first 6 months. The most common adverse reactions reported for at least 20% of pembrolizumab-treated patients included fatigue, musculoskeletal pain, pruritus, decreased appetite, nausea

Full access

Distress Management, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology

Michelle B. Riba, Kristine A. Donovan, Barbara Andersen, IIana Braun, William S. Breitbart, Benjamin W. Brewer, Luke O. Buchmann, Matthew M. Clark, Molly Collins, Cheyenne Corbett, Stewart Fleishman, Sofia Garcia, Donna B. Greenberg, Rev. George F. Handzo, Laura Hoofring, Chao-Hui Huang, Robin Lally, Sara Martin, Lisa McGuffey, William Mitchell, Laura J. Morrison, Megan Pailler, Oxana Palesh, Francine Parnes, Janice P. Pazar, Laurel Ralston, Jaroslava Salman, Moreen M. Shannon-Dudley, Alan D. Valentine, Nicole R. McMillian, and Susan D. Darlow

with substantial long-term side effects, such as fatigue, pain, anxiety, and depression, that interfere with patients’ ability to perform daily activities. In addition, the physiologic effects of cancer itself and certain anticancer drugs can also be

Full access

NCCN Guidelines Updates: Management of Muscle-Invasive Bladder Cancer

Thomas W. Flaig

anti–PD-L1 checkpoint inhibitors have similar side-effect profiles. At least 20% of patients in the trial experienced side effects, such as fatigue, pruritus, musculoskeletal pain, and decreased appetite. 3 “Immunotherapy may activate many organ systems

Full access

Surgical Management of Colorectal Cancer in the Laparoscopic Era: A Review of Prospective Randomized Trials

Mark Bloomston, Henry Kaufman, John Winston, Mark Arnold, and Edward Martin

. Postoperative pain and fatigue after laparoscopic or conventional colorectal resections. A prospective randomized trial . Surg Endosc 1998 ; 12 : 1131 – 1136 . 15 Stage JG Schulze S Moller P . Prospective randomized study of laparoscopic versus

Full access

NCCN Guidelines Insights: Prostate Cancer, Version 1.2021

Featured Updates to the NCCN Guidelines

Edward Schaeffer, Sandy Srinivas, Emmanuel S. Antonarakis, Andrew J. Armstrong, Justin E. Bekelman, Heather Cheng, Anthony Victor D’Amico, Brian J. Davis, Neil Desai, Tanya Dorff, James A. Eastham, Thomas A. Farrington, Xin Gao, Eric Mark Horwitz, Joseph E. Ippolito, Michael R. Kuettel, Joshua M. Lang, Rana McKay, Jesse McKenney, George Netto, David F. Penson, Julio M. Pow-Sang, Robert Reiter, Sylvia Richey, Mack Roach, III, Stan Rosenfeld, Ahmad Shabsigh, Daniel E. Spratt, Benjamin A. Teply, Jonathan Tward, Dorothy A. Shead, and Deborah A. Freedman-Cass

(range, 1.9 to ≥21.8 months). The most common adverse effects with pembrolizumab were fatigue, pruritus, diarrhea, anorexia, constipation, nausea, rash, fever, cough, dyspnea, and musculoskeletal pain. Pembrolizumab also may be associated with immune

Full access

The Future of Geriatric Oncology Research: Moving Toward Interventions and Objective Biomarkers of Aging

Efrat Dotan

patients with cancer reported improvement in treatment tolerance, cancer-related fatigue, and QoL with participation in exercise programs during therapy. 8 A few studies evaluating exercise programs specifically among older adults with cancer have shown